One of the primary
concerns in the field of green synthesis
of
nanoparticles (NPs) utilizing plant materials is the scarcity of high
purity, challenges in achieving large-scale production, and limited
global accessibility. Hygienic preparation and safe storage of plant
extracts are also considerable challenges in this field. So, an investigation
was started to overcome these limitations. Virgin coconut oil (VCO)
in its purest form is available commercially all over the world. Also,
it has high medicinal value with excellent biomedical applications.
Very limited work has been reported on oils as bio reducers and stabilizers.
In those reports, they used a few chemicals as mediators in the processes
of synthesis and cleaning. So, to the best of our knowledge, for the
first time, zinc oxide (ZnO) NPs were synthesized using VCO as a reducing
and capping agent with zero chemical mediators. A comprehensive investigation
of the structural, microstructural, and optical properties was reported.
X-ray diffraction confirms the formation of VCO-ZnO NPs with an average
crystallite size of 32.81 nm in a hexagonal structure. UV characteristics
confirm quantum confinement through a well-defined SPR near 223 nm
with fwhm of 67 nm and a direct band gap at 3.96 eV. FTIR reveals
the capping of VCO through carboxylic functional groups, particularly
the −COO– group of coconut oil at 1770 cm
–1
with a shift of about 30 cm
–1
compared to plain
VCO. TEM confirms the polycrystalline nature with nearly spherical
and 10–22 nm particle size. The zeta potential of −15.4
± 5.0 mV signifies the stability and antiagglomeration properties.
FESEM with EDS results confirms morphological excellence, the purity
level of synthesized NPs (99.5%), and the prominent scalability of
NPs (84.38% yield). Finally, as-synthesized VCO-ZnO NPs showed very
good antioxidant (IC
50
78.991, 51.464, and 4.677 μg/mL
in DPPH, ABTS, and FRAP assays, respectively), anti-inflammatory (IC
50
22.42 μg/mL in protein denaturation), antimicrobial
(MIC 0.156 mg/mL for
Pseudomonas
and
0.316 mg/mL for
S. aureus
), and antidiabetic
properties (IC
50
88.45 and 147.67 μg/mL for α-amylase
and α-glucosidase assays, respectively).